Abstract
Objectives
This evaluation assesses the quantity, uniqueness, and innovative nature of the past 20 years of Rx-to-OTC (RTO) switches, where a current prescription (Rx) product is reclassified for over-the-counter (OTC) status. Broadening access to more OTC drugs with well-established safety and efficacy could help to reduce healthcare expenditure and address public health challenges.
Methods
The FDA-maintained RTO switch list website was accessed to generate the primary dataset. Each product listed was assessed for the current OTC availability in the United States of its active ingredient, pharmacological class, and indication to determine its innovative quality. Descriptive statistics were employed in this study.
Results
From January 2002 through August 2022 there were 45 RTO switches. Among these, 51.1% involved a new to OTC active ingredient, 22.2% involved a new pharmacological class, 6.6% involved a new indication, and 82.2% were considered follow-on products that introduced a new to OTC active ingredient or new dosage form of an already marketed active ingredient to treat an existing OTC indication. A small minority (6.6%) were considered an exceptional innovation that would offer US consumers a genuinely novel OTC product, providing a new to OTC active pharmaceutical ingredient, pharmacological class, and indication. Overall, there was 1 exceptional innovation every 6.7 years.
Conclusions
Over 40 RTO switches have come to the OTC market in the past 20 years; however, exceptional innovations that expand access to new to OTC active ingredients for new indications are rare. Policies and strategies that result in more innovative switches that can benefit consumers and public health should be evaluated.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
RTO switches occur when the FDA approves a sponsor’s new drug application or supplemental application for OTC status of a current Rx product. An RTO switch can manifest in two distinct forms: as a full RTO switch or as a partial RTO switch. A full RTO switch is when the current Rx-only NDA is switched to OTC status in its entirety, with no prescription availability remaining post-switch. A partial RTO switch is when a sponsor seeks to convert only some conditions of use (such as a specific dose or indication) to OTC status. This type of RTO switch requires the sponsor to submit a new NDA. Both types of RTO switches require a data package outlining the safety and efficacy for use as an OTC product. This assists the FDA in determining the risk–benefit of switching the prescription product to OTC status. The data package may include data from existing or new randomized controlled trials as well as data and information associated with the post-marketing safety experience. In addition to information related to safety and efficacy, the sponsor is often required to conduct consumer label comprehension studies and self-selection studies [1,2,3]. Label comprehension studies usually involve the recruitment of participants that reflect the general population to review a proposed OTC label and answer questions to determine whether the label can be sufficiently understood. Self-selection studies involve participants that would be consistent with the proposed product’s target population to determine whether respondents can adequately assess whether or not the product is appropriate for themselves.
Certain RTO switch programs will include an actual use study, which is an evaluation of the proposed product under simulated real world OTC conditions, without the supervision of a healthcare provider. Following the NDA submission by the sponsor, the FDA may choose to convene a non-prescription drug advisory committee meeting to seek input from the public as well as independent advisors on various aspects of the proposed RTO switch [4].
RTO switches offer the opportunity to continue disease awareness and education while greatly expanding access to safe and effective medications that are often at a lower cost and greater convenience than when only available by prescription [5, 6]. The need for innovative OTC options is critical, particularly with existing inequities in the US healthcare system [7], coupled with an increasing population of informed consumers with greater access to education about medical conditions and medications [8,9,10,11]. Broadening access to more OTC drugs with well-established safety and efficacy could help to address public health challenges including cost concerns, shortage of physicians, accessibility, healthcare inequality, lost productivity, and undertreatment of certain conditions [6, 12,13,14,15]. Accessible OTC treatment options can also help alleviate burden on the healthcare system, allowing patients to self-treat. Greater patient and consumer autonomy in healthcare can empower a more health-conscious and informed population. The objective of this research was to quantify the innovative nature of the past 20 years of RTO switches that have been FDA-approved in the US (2002–2022).
Materials and Methods
The FDA-maintained RTO switch list website was accessed to generate the primary dataset [16]. Each product listed was assessed for its active ingredient, pharmacological class, and indication to determine its innovative qualities. Innovative qualities were assessed in relation to whether the active ingredient, pharmacological class, or indication were previously available OTC in the United States. A “new to OTC active ingredient” was defined as a novel active pharmaceutical ingredient that was not previously available in a marketed OTC product. A “follow-on product” was defined as a new dosage form of an already marketed active ingredient or a new product that offers a new to OTC active ingredient within a pharmacological class and indication that already exists on the OTC market. These are sometimes also referred to as “me-too” products. A “new pharmacological class” was defined as a product within a class of drugs that was not previously available to consumers in a marketed OTC product prior to the switch. A “new indication” was defined as a product that introduced a novel OTC indication that was not previously FDA approved for consumers. An “exceptional innovation” was defined as one that introduced a new to OTC active pharmaceutical ingredient, pharmacological class, and indication in the same switch of which none were previously available in the OTC marketplace. Descriptive statistics were employed in this study.
Results
From January 2002 through August 2022 there were 45 RTO switches. Over this period, a significant majority (82.2%) of switches were follow-on products. Just over half (51.1%) involved a new to OTC active pharmaceutical ingredient with less than one-fourth (22.2%) providing a new pharmacological class of medications. Three switches (6.6%) were considered exceptional innovations (Table 1). As such, for every one exceptional innovation, there were 12 follow-on products. On average, during the study period, there was one exceptional innovation RTO switch every 6.7 years.
Figure 1 displays the switches over time demonstrating the increasing number of switches that are simply follow-on products (Fig. 1). Products that are predominantly for seasonal allergies (29/45) or for gastrointestinal symptoms (6/45) form a large proportion (64 and 13%, respectively) of switches in the observation period (Supplemental Material). Out of the nine new pharmacological classes switched during the last 20 years, only 4 (44.4%) primarily function via the systemic route (Supplemental Material).
Three exceptional products were identified over the entire observation period (Table 2). These RTO switches include levonorgestrel for emergency contraception, orlistat for weight loss, and oxybutynin for overactive bladder in women.
Discussion
The main results from this analysis demonstrate that there are two or three RTO switches per year, on average. Exceptional innovations that offer novel active ingredients for unprecedented indications are extremely rare. To our knowledge this is the first analysis of this kind.
Simply viewing the RTO switches during the past 20 years leads one to observe that the majority of new pharmacological class switches (5 out of 9) work via the non-systemic route (Supplemental Material). These agents (polyethylene glycol 3350, orlistat, triamcinolone acetonide, adapalene, and ivermectin) do not achieve appreciable systemic absorption and their action is limited to a certain function or area of the body. The four remaining agents work systemically (Supplemental Material). However, it is important to note that the last systemically acting new pharmacological class to enter the market as a switch was a competitive antagonist for acetylcholine in the form of transdermal oxybutynin in 2013, nearly 10 years ago (Supplemental Material). It is unclear what has led to this relatively long absence of systemically active RTO switches; however, the underlying reasons should be investigated. This is where open dialogue and debate can play a role to support products that can offer potential opportunities to address important therapeutic gaps.
Over the observation period, it appears as if many new to OTC active ingredients are entering the market as switches, but looking more closely at the data shows that an overwhelming majority are follow-on products, not innovative products. The influx of new to OTC active ingredients as follow-on products within the same pharmacologic class may, however, increase competition, allow for broader consumer choices, and result in lower prices for consumers. Ultimately, the underlying issues that limit exceptional innovations in the OTC drug marketplace remain unclear.
Certainly, as indications for potential OTC drugs become more complex, confirming safe and effective use by consumers may be challenging. Despite theoretical concerns, there remains several possible opportunities for novel OTC drugs.
OTC statins (HMG-CoA reductase inhibitors) have long been discussed as an opportunity to address undertreatment of elevated cholesterol and for the reduction of vascular events including myocardial infarctions and strokes [17, 18]. Despite the potential for substantial benefits, several issues raised by certain stakeholders have impeded the opportunity associated with OTC statins. These include challenges with appropriate self-diagnosis, as well possible overtreatment or undertreatment of the condition. A new approach to bringing rosuvastatin directly to consumers is being investigated, although the consumer experience is unclear and appears to break from traditional means of acquiring OTC drugs [19, 20]. This approach incorporates technology, specifically a self-accessed web-based application on an internet capable device, to qualify a consumer for purchasing rosuvastatin based on their responses [19, 20]. This deviates from the traditional retail approach to accessing OTC drugs. Adding barriers to accessing OTC drugs that can otherwise be used safely and effectively under usual conditions, such as making the product e-commerce only, limiting distribution to certain retail establishments, requiring mobile application downloads, incorporating lengthy questionnaires, or requiring to add detailed biometric data (such as blood pressure), introduces some of the same challenges that are present for prescription products and would do little to address the undertreatment and lack of adherence concerns.
In addition to statins, other novel OTC drugs can and should be seriously considered, as described further below. Recently, nonprescription oral contraceptives have come into focus [21]. These products are undergoing the required testing for OTC use, however, given the important differences between progesterone-only pills and combination estrogen-progesterone options, it appears that the latter have more challenges related to self-selection, such as blood pressure and smoking warnings as well as thromboembolic concerns. [22]. Again, barriers that limit progress for bringing novel OTC switches to the market should be justifiable rather than simply based on theoretical concerns. Furthermore, potential safety concerns as well as product benefits can be examined in clinical studies that simulate a naturalistic OTC environment to assess whether potential or theoretical issues would sufficiently undermine the benefits of the product [23].
Prior to receiving regulatory approval, theoretical concerns have been linked to many OTC switch candidates. These include teratogenic concerns related to adapalene [24], sexual promiscuity concerns related to levonorgestrel [25, 26], and adrenal suppression associated with nasally administered corticosteroids [27]. There is no apparent evidence to suggest that these theoretical concerns have been observed in a nonprescription setting, although the absence of such research does not necessarily confirm there is no risk.
Several countries around the world have made a wide variety of medications, from a diverse range of therapeutic areas, available without a prescription [28]. These observations outline potential opportunities for novel/exceptional OTC switches within the United States, such as medications for acute migraine [29, 30], erectile dysfunction [31, 32], lower urinary tract symptoms in men [33, 34], and antiviral therapy for influenza infection in adults [35]. Beyond these, one could even envision more advanced conditions that often go undertreated as potential targets to address public health concerns. This could include interventions such as rescue therapy for asthma [36]. Technological advances and consumers’ adeptness with technology may make these potentially more complex conditions achievable [37,38,39]. Simple technology-based solutions, such as web-based self-screening aids that could be accessed on a smartphone along with the expanded space for label information afforded by the interactive interface, may help to facilitate the development of novel OTC drugs. Patient ability to manage their health via technology has been demonstrated extensively with the advent of FDA-cleared medical devices for monitoring heart rate and blood pressure, among other conditions [40,41,42,43,44]. About 10 years ago, the FDA introduced the Nonprescription Safe Use Regulatory Expansion (NSURE) initiative to potentially inspire approaches by sponsors to implement technology to facilitate explorations into more challenging areas [45]. Unfortunately, as evidenced by the present analysis, no advances for consumers have emerged from this initiative.
An evolution to NSURE appears to now be developing in the form of a new proposed rule regarding Additional Conditions for Nonprescription Use (ACNU) from the FDA [46]. The proposed rule outlines many requirements for sponsors and potentially even some disincentives such as dual marketing status for prescription and OTC drugs for the same indication and dose. Under this proposed rule, when labeling alone is not sufficient to ensure that the consumer can appropriately self-select, appropriately use, or both, a sponsor may submit an application proposing an ACNU [46]. While the concept of welcoming more switches via a technology-based approach appears attractive, caution should be exercised pertaining to this idea. If requirements for consumers are substantial and onerous, the technology may prove to produce some of the same inequities that are currently seen in the US healthcare system [47,48,49].
OTC drugs provide significant benefits in terms of direct and indirect cost-effectiveness for populations that are frequently underserved by the United States healthcare system [50,51,52]. These groups include people of color, those with lower socioeconomic status, people living in rural areas, and those with no medical insurance or insufficient insurance. If novel OTC drugs are to be successful, they need to serve these groups. To do so, access requirements should be limited rather than burdensome. Bringing a new OTC drug to market with unnecessarily complex requirements will almost certainly not help to address public health concerns and could potentially do more harm than good, particularly from public relations and policy viewpoints. Efforts should be made to mitigate concerns rather than determining success only when all potential issues are fully eliminated. Creating insurmountable obstacles or burdensome restrictions is effectively a decision to leave the status quo in place. Overall benefits and risks in the intended treatment population should be viewed at a macroscopic level, otherwise there are sure to be many missed opportunities to bring solutions to the marketplace. This issue is illustrated with the case of nonprescription statin therapy, where population level benefits appear to outweigh the potential risks [17, 53, 54]. To date, few high impact RTO switches have even made it far enough in the development process to reach an advisory committee such that all interested stakeholder groups can participate in the process.
The primary limitation of this study is that only products included in the FDA RTO switch list were considered. Direct-to-OTC products, devices, and any other consumer medical product were not considered. The data are also limited to approximately the last 20 years. Details before this point are limited but could add perspective.
Conclusion
In conclusion, while there is great potential for novel OTC drugs to help support consumer autonomy and meaningfully advance public health, particularly for undertreated conditions, relatively few drugs that stem from prescription products have been approved over the last two decades. Many of them have simply followed previously existing products and/or conditions. Despite over 40 RTO switches occurring within the past 20 years, exceptional advancements that expand access to new to OTC active ingredients for new indications remain rare. The underlying practical and policy challenges inhibiting more switches from coming to the market should be investigated.
Data Availability
The data that support the findings of this study are available in the FDA Prescription to Over-the-Counter Switch List at https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/prescription-over-counter-otc-switch-list.
References
U.S. Food and Drug Administration. Prescription-to-Nonprescription (Rx-to-OTC) Switches. https://www.fda.gov/drugs/drug-application-process-nonprescription-drugs/prescription-nonprescription-rx-otc-switches.
U.S. Food and Drug Administration. Guidance for Industry Label Comprehension Studies for Nonprescription Drug Products. https://www.fda.gov/media/75626/download.
U.S. Food and Drug Administration. Guidance for Industry Self-Selection Studies for Nonprescription Drug Products. https://www.fda.gov/media/81141/download.
U.S. Food and Drug Administration. Nonprescription Drugs Advisory Committee. https://www.fda.gov/advisory-committees/human-drug-advisory-committees/nonprescription-drugs-advisory-committee.
Shiffman S, Sweeney CT. Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability? Health Policy. 2008;86(1):17–26.
Shiffman S, Gitchell J, Pinney JM, et al. Public health benefit of over-the-counter nicotine medications. Tob Control. 1997;6(4):306–10.
Dickman SL, Himmelstein DU, Woolhandler S. Inequality and the health-care system in the USA. Lancet. 2017;389(10077):1431–41.
Kraft FB, Goodell PW. Identifying the health conscious consumer. J Health Care Mark. 1993;13(3):18–25.
Packaged Facts. Functional foods: Key trends & developments in ingredients: market research report. https://www.packagedfacts.com/Functional-Foods-Key-8540424/.
Iqbal J, Yu D, Zubair M, et al. Health consciousness, food safety concern, and consumer purchase intentions toward organic food: the role of consumer involvement and ecological motives. SAGE Open. 2021;11(2):1.
Iversen AC, Kraft P. Does socio-economic status and health consciousness influence how women respond to health related messages in media? Health Educ Res. 2006;21(5):601–10.
Brass EP. Changing the status of drugs from prescription to over-the-counter availability. N Engl J Med. 2001;345(11):810–6.
Camp SL, Wilkerson DS, Raine TR. The benefits and risks of over-the-counter availability of levonorgestrel emergency contraception. Contraception. 2003;68(5):309–17.
Newton G, Popovich NG, Pray WS. Rx-to-OTC switches: from prescription to self-care. J Am Pharm Assoc. 1996;NS36(8):488–95.
Zhang X, Lin D, Pforsich H, et al. Physician workforce in the United States of America: forecasting nationwide shortages. Hum Resour Health. 2020;18(1):8.
Center for Drug Evaluation and Research. Prescription to Over-the-Counter (OTC) switch list. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/prescription-over-counter-otc-switch-list.
Melin JM, Struble WE, Tipping RW, et al. A consumer use study of over-the-counter lovastatin (CUSTOM). Am J Cardiol. 2004;94(10):1243–8.
Brass EP, Vassil T, Replogle A, et al. Can consumers self-select for appropriate use of an over-the-counter statin? The self evaluation of lovastatin to enhance cholesterol treatment study. Am J Cardiol. 2008;101(10):1448–55.
Nissen SE, Hutchinson HG, Wang TY, et al. Technology-assisted self-selection of candidates for nonprescription statin therapy. J Am Coll Cardiol. 2021;78(11):1114–23.
ClinicalTrials.gov. Technology-assisted cholesterol trial in consumers (TACTiC). https://ClinicalTrials.gov/show/NCT04964544.
Financial Times. US considers first over-the-counter birth control pill. https://www.ft.com/content/19599dda-7f4d-41d3-8b27-5eb16aadb458.
The New York Times. F.D.A. to weigh over-the-counter sale of contraceptive pills. https://www.nytimes.com/2022/07/11/us/politics/fda-contraception-pill-hra-pharma.html.
Brass EP. The gap between clinical trials and clinical practice: the use of pragmatic clinical trials to inform regulatory decision making. Clin Pharmacol Ther. 2009;87(3):351–5.
Center for Drug Evaluation and Research. Summary minutes: nonprescription drugs advisory committee meeting, Gaithersburg, MD, 15 April 2016.
Wood AJJ, Drazen JM, Greene MF. A sad day for science at the FDA. N Engl J Med. 2005;353(12):1197–9.
Leagle. TUMMINO v. TORTI. https://www.leagle.com/decision/20091122603aufsupp2d51911076.
Center for Drug Evaluation and Research. Summary minutes: nonprescription drugs advisory committee meeting, Silver Spring, MD, 31 July 2013.
Gauld NJ, Kelly FS, Kurosawa N, et al. Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison. PLoS ONE. 2014;9(9):e107726.
Australian Government Department of Health and Aged Care; Therapeutic Goods Administration. Final decisions made pursuant to regulation 42ZCZR—proposals referred to the November 209 Advisory Committee on Medicines Schedule (ACMS #28). https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decisions-amend-or-not-amend-current-poisons-standard-may-2020/11-sumatripan.
Diener H-C, Dowson A, Whicker S, et al. Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan. J Headache Pain. 2008;9(6):359–65.
Medicines and Healthcare products Regulatory Agency. MHRA reclassifies Viagra connect tablets to a pharmacy medicine. https://www.gov.uk/government/news/mhra-reclassifies-viagra-connect-tablets-to-a-pharmacy-medicine.
Sanofi. Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial. https://www.sanofi.com/en/media-room/press-releases/2022/2022-05-30-05-30-00-2452303.
The Pharma Letter. UK regulatory agency clears prostate drug Flomax for OTC use; generic competition due next year in USA. https://www.thepharmaletter.com/article/uk-regulatory-agency-clears-prostate-drug-flomax-for-otc-use-generic-competition-due-next-year-in-usa.
Roehrborn CG, Lowe FC, Gittelman M, et al. Management of male lower urinary tract symptoms in a simulated, over-the-counter setting: an exploratory study of tamsulosin. Drugs Aging. 2019;36(2):179–88.
Sanofi. Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care. https://www.sanofi.com/en/media-room/press-releases/2019/2019-07-23-05-00-00-1886144.
Feldman WB, Avorn J, Kesselheim AS. Switching to over-the-counter availability of rescue inhalers for asthma. JAMA. 2022;327(11):1021–2.
Sim R, Lee SWH. Patient preference and satisfaction with the use of telemedicine for glycemic control in patients with type 2 diabetes: a review. Patient Prefer Adherence. 2021;15:283–98.
Jain T, Lu RJ, Mehrotra A. Prescriptions on demand: the growth of direct-to-consumer telemedicine companies: the growth of direct-to-consumer telemedicine companies. JAMA. 2019;322(10):925–6.
Mehrotra A, Huskamp HA, Souza J, et al. Rapid growth in mental health telemedicine use among rural medicare beneficiaries, wide variation across states. Health Aff (Millwood). 2017;36(5):909–17.
Valle J, Godby T, Paul DP 3rd, et al. Use of smartphones for clinical and medical education. Health Care Manag (Frederick). 2017;36(3):293–300.
OMRON Healthcare. OMRON® Healthcare officially launches HeartGuideTM, the first wearable blood pressure monitor, with new digital health service, HeartAdvisor™. https://omronhealthcare.com/press-release/omron-healthcare-officially-launches-heartguide-first-wearable-blood-pressure-monitor-new-digital-health-service-heartadvisor/.
U.S. Food and Drug Administration. Re: DEN180044. https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180044.pdf.
Google. New Fitbit feature makes AFib detection more accessible. https://blog.google/products/fitbit/irregular-heart-rhythm-notifications/.
U.S. Food and Drug Administration. FDA permits marketing of new device designed to reduce sleep disturbance related to nightmares in certain adults. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-new-device-designed-reduce-sleep-disturbance-related-nightmares-certain-adults.
U.S. Food and Drug Administration. Nonprescription drug safe use regulatory expansion (NSURE). https://www.fda.gov/media/85156/download.
U.S. Food and Drug Administration. The FDA announces proposed rule: nonprescription drug product with an additional condition for nonprescription use. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/fda-announces-proposed-rule-nonprescription-drug-product-additional-condition-nonprescription-use.
Weinstein JN, Geller A, Negussie Y, et al. Communities in action pathways to health equity. Washington, DC: National Academies Press; 2017. p. 99–184.
Braveman P. Health disparities and health equity: concepts and measurement. Annu Rev Public Health. 2006;27(1):167–94.
World Health Organization. Health inequities and their causes. https://www.who.int/news-room/facts-in-pictures/detail/health-inequities-and-their-causes.
Consumer Healthcare Products Association. The value of OTC medicines to the U.S. healthcare system. https://www.chpa.org/about-consumer-healthcare/research-data/research-reports/value-otc-medicines-us-healthcare-system-0.
Consumer Healthcare Products Association. The value of OTC medicines. https://www.chpa.org/about-consumer-healthcare/activities-initiatives/value-otc-medicines.
Klepser ME. Socioeconomic impact of seasonal (epidemic) influenza and the role of over-the-counter medicines. Drugs. 2014;74(13):1467–79.
Brass EP, Allen SE, Melin JM. Potential impact on cardiovascular public health of over-the-counter statin availability. Am J Cardiol. 2006;97(6):851–6.
Stomberg C, Albaugh M, Shiffman S, et al. A cost-effectiveness analysis of over-the-counter statins. Am J Manag Care. 2016;22(5):e294-303.
Acknowledgements
We acknowledge the review and commentary by May Smith and Vidhu Dev.
Funding
This study did not receive any funding support.
Author information
Authors and Affiliations
Contributions
MF: Assisted in data acquisition, interpretation, inputting data into graphical form, and drafting of the manuscript. Provided final approval of the version to be published. Ensured accuracy and integrity of the research. KR: Assisted in data acquisition, interpretation, drafting of the manuscript, inputting data into tabular form, and formatting for final publication. Provided final approval of the version to be published. Ensured accuracy and integrity of the research.
Corresponding author
Ethics declarations
Conflict of interest
Matt Fisher is employed by Haleon. Haleon is a manufacturer and marketer of consumer healthcare products. Kapil Rawal is employed by Rutgers University and is affiliated with Haleon via the Rutgers Institute of Pharmaceutical Industry Fellowships.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Fisher, M., Rawal, K. A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches. Ther Innov Regul Sci 57, 1074–1080 (2023). https://doi.org/10.1007/s43441-023-00547-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43441-023-00547-9